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Abstract Although MOR-1 encodes a mu opioid receptor, its 
relationship to the pharmacologically defined mu receptor sub- 
types has been unclear. Antisense mapping now suggests that 
these subtypes result from alternative splicing of MOR-1. Three 
oligodeoxynucleotide probes targeting exon 1 and another oli- 
godeoxynucleotide irected against the coding region of exon 4 
block supraspinal morphine analgesia, a mu~ action, while five of 
six oligodeoxynucleotides directed against exons 2 and 3 are 
inactive. Inhibition of gastrointestinal transit and spinal morphine 
analgesia, two mu 2 actions, are blocked only by the probe against 
exon 4 and not by those directed against exon 1. In contrast, the 
analgesic actions of the extraordinarily potent mu drug morphine- 
6~-glncuronide are blocked by six different antisense oligode- 
oxynucleotides targeting exons 2 and 3, but not by those acting 
on exons 1 or 4. These results suggest that the mu~ and mn 2 
receptor subtypes originally defined in binding and pharmacologi- 
cal studies result from alternative splicing of MOR-I while mor- 
phine-6/]-glucuronide acts through a novel, previously unidenti- 
fied receptor which is yet another MOR-1 splice variant. 
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1. Introduction 
Morphine acts through mu receptors to elicit a variety of 
pharmacological ctions, including analgesia, respiratory de- 
pression and the inhibition of gastrointestinal transit (for re- 
view, see [1]). Evidence from a variety of approaches has sug- 
gested that these actions are mediated through distinct mu 
(morphine) receptor subtypes initially proposed from tradi- 
tional binding studies [2-5] and detailed computer modeling 
approaches [6-9]. Mui actions, defined in large part by their 
sensitivity towards naloxonazine [10], include supraspinal mor- 
phine analgesia, while mu2 receptors mediate spinal morphine 
analgesia, respiratory depression, the inhibition of gastrointes- 
tinal transit and most signs associated with morphine depend- 
ence [1]. However, the actions of another mu drug, morphine- 
6fl-glucuronide [11,12], remain unclear. Binding experiments 
reveal that its affinity for mu receptors is slightly less than 
morphine while antagonist studies confirm that it acts through 
mu receptors [11,12]. Yet morphine-6/~-glucuronide is at least 
100-fold more potent han morphine in vivo, raising the possi- 
bility of a yet another mu receptor subtype. 
Only one mu receptor, MOR-1, has been cloned [13-22]. 
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When expressed, it shows the anticipated selectivity in both 
binding and functional assays for mu, as opposed to delta or 
kappa, ligands. Although a splice variant involving the terminal 
portion of the COOH terminus has been reported in both 
human and rat clones [23,24], these two variants do not explain 
the distinct mu subtypes inferred from the pharmacological 
studies [2-7,9]. 
Initial antisense approaches [15] establishing the pharmacol- 
ogical significance of the recently cloned mu (MOR-I) [25], 
kappa 1(KOR-1) [26] and delta (DOR-1) receptors [27,28] were 
quickly confirmed [29-33]. Antisense oligodeoxynucleotides 
against DOR-1 downregulate mRNA and protein levels in both 
NG108-15 cells and intrathecally in mice [28], as predicted. 
Antisense probes are highly selective and specific. Downregu- 
lating one opioid receptor does not interfere with the activity 
of other subtypes. Indeed, changing the sequence of only four 
bases renders the oligodeoxynucleotide nactive. Equally im- 
portant, the antisense probes are effective regardless of which 
region along the mRNA is targeted [27]. Morphine analgesia 
is blocked by an antisense oligodeoxynucleotide irected 
against the 5'-untranslated region of MOR-1 [25], while an 
antisense probe active against kappa~ analgesia targeted the 
middle of the coding region of KOR- 1 [26], Five different anti- 
sense oligodeoxynucleotides irected against different regions of 
the DOR-1 mRNA lower [3H]DPDPE binding in NG108-15 
cells [27] and block intrathecal DPDPE analgesia equally well 
(G.R. Rossi and G.W. Pasternak, unpublished observations). 
The ability to effectively target any region of a cDNA with 
antisense oligodeoxynucleotides provides an opportunity to ex- 
plore the functional relevance of partial cDNA sequences with- 
out cloning a full length cDNA, as illustrated by our recent 
cloning of KOR-3 [15,34,35], a fourth member of the opioid 
receptor family [15,3643]. It also opens the possibility of using 
antisense to assess the presence of specific exons in the active 
protein, as we recently demonstrated with KOR-3 [34,35]. 
Thus, antisense mapping provides the opportunity to explore 
the possibility of functionally important splice variants which 
have not yet been identified from cloning studies. We now 
present evidence suggesting the presence of pharmacologically 
relevant splice variants of MOR-I corresponding to mu~ and 
mu2 receptors as well as a novel receptor esponsible for the 
actions of morphine-6fl-glucuronide. 
2. Materials and methods 
2.1. Materials 
Male CD-I mice (25-35 g; Charles River Breeding Laboratory, 
Bloomington, MA) were used in all studies. Animals were housed five 
per cage, maintained on a 12-h light/dark cycle and given ad libitum 
access to food and water. Morphine sulfate and morphine-6fl-glucu- 
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ronide were obtained from the Research Technology Branch of the 
National Institute on Drug Abuse (Rockville, MD). Oligodeoxynucleo- 
tides were synthesized by The Midland Certified Reagent Co. (Mid- 
land, TX) or bs. the core facility at MSKCC. DNA modification and 
restriction enzymes were from Gibco (Gaithersberg, MD), Stratagene 
(LaJolla, CA) or New England Biolabs (Beverly, MA). DNA sequenc- 
ing kits were from U.S. Biochemical Corp. (Cleveland, OH). Nyhm 
membranes were purchased from Micron Separation Inc. (Boston, 
MA). GeneScreen Plus and all radiochemicals were purchased from 
DuPont-NEN (Boston. MA) unless stated otherwise. All other chemi- 
cals and reagents were purchased from Sigma (St. Louis, MO), unless 
otherwise noted. Halothane was purchased from Halocarbon Labora- 
tory (Hackensack, NJ). 
2.2. (7oning the mouse MOR-I 
Cloned cDNA encoding the mouse homolog of MOR-1 was isolated 
from a Y-RACE-ready cDNA (Clontech) by PCR using 5' anchor sense 
primer and 3' antisense primer (5' CTC TAG ACT CCA GGA ATG 
ACT TTG AAT GCA GGA 3') designed to the rat MOR-1 sequence 
(GenBank accession #L13069) at positions 1518 1537. The PCR frag- 
ment was subcloned into EcoRl/XbaI sites of Bluescript SK and se- 
quenced. Comparison of the sequence (GenBank Accession # U26915) 
to the published mouse MOR-I sequence [22] and an unpublished 
mouse MOR-1 sequence (Drs. D. Kaufman and C. Evans, unpublished 
observations) hows 99.9 and 99.2% identity, respectively. All the anti- 
sense oligodeoxynucleotides are complimentary to cDNA sequences 
identical among all three sequences, with the exception of Antisense K
Table 1 
Effects o1" antisense treatment on supraspinal morphine analgesia 
Analgesic response n P 
Control 74% 105 
Mismatch 60% 15 0.195 
Antisensc 
Exon 1 A 26% 70 <0.0001 
B 40% 20 0.008 
C 25% 20 0.0001 
Exon 2 D 75% 20 0.497 
E 74% 19 0.548 
F 72% 25 0.590 
Exon 3 G 65% 20 0.368 
H 80% 45 0.197 
I 35% 20 0.001 
Exon 4 J 20% 20 <0.0001 
K 80% 20 0.410 
The antisense oligodeoxynucleotides w re based upon our sequence of 
the mouse homolog of MOR-1. Their calculated Tm values and posi- 
tions based upon our cDNA sequence (GenBank Accession # U26915) 
are as follows: A: CGC CCC AGC CTC TTC CTC T, 60.1 °C, 195 213: 
B:GTT GAG CCA GGA GCC AGG T, 56.2°C, 357 375: C: GCC 
CAC TAC ACA CAC GAT AGA, 52.2°C, 508 528; D: TTG GTG 
GCA GTC TTC ATT TTG G, 58.4°C, 572 593; E: GCC TGT ATT 
TTG TGG TTG CCA T, 57.4°C, 895 916; F: GGA CCC CTG CCT 
GTA TTT TGT G, 59.1 °C, 904-924: G: TGA GCA GGT TCT CCC 
AGT ACC A, 58.2°C, 959 979; H: CCA CCA GCA CCA TCC GGG, 
61.5°C, 1118 I135; I :CACTGTATTAGCCGTGGAGGG,  55.8°C, 
1402 1422: J: GGG CAA TGG AGC AGT TTC TG, 56.7°C, 1457 
1476: K: CAG GAA ACC AGA GCC TCC CA, 58.5°C, 1558 1577. 
The mismatch oligodeoxynucleotide, based upon antisense A, had the 
following sequence with the switched bases underlined: CGC CCC 
GAC CTC TTC CCT T. Based upon the gene structure of mouse 
MOR-1 [22], the location of the antisense probes is as follows: Exon 
1: A, B and C; Exon 2: D, E and F: Exon 3: G, H and I; Exon 4: J and 
K. Note that F spans the junction between exons 2 and 3. Since 17 bases 
are in exon 2 and only 5 are in exon 3, we assume that its activity is 
predominantly against exon 2. Groups of mice received the indicated 
antisense oligodeoxynucleotide on days 1, 3 and 5 as described in 
Section 2. Analgesia was assessed on day 6 with morphine (0.7 ,ug, 
i.c.v.). Signiticance in the analgesic assays was assessed using the Fisher 
exact test. Slatistically significant results are bolded. 
Antisense 
Antisense mapping MOR-1 
5' 3' 
~' ..... - -~  '~  MOR-I  
A B C D E F G H I J K 
Supraspinal + + + + + - -  
Analgesia 
Analgesia __ __ +. 
GI Transit + - -  
Morphine-6[3 
glucuronide - ~ j 
Supraspinal + + + + + + 
.analgesia 
M6G 
Fig. 1. Antisense mapping MOR-1. The four exons of MOR-I are 
presented schematically. The various assays are given on the left, while 
the putative receptor classification is on the right. Activity of various 
oligodeoxynucleotides in each of the four assays are summarized with 
+ representing a statistically significant blockade of activity and - 
representing o significant change. Exons corresponding to MOR-I are 
shaded, while those probably reflecting alternatively spliced exons are 
not, 
which is identical to that of Drs. Kaufman and Evans but differs from 
that of Loh and colleagues [22] by a single base difference at position 
1566 (T/G). 
2.3. Antisense /reatments 
Groups of mice received the stated antisense (5 ,ug) or mismatch (5 
/tg) oligodeoxynucleotide or vehicle alone (0.9% saline) intracerebrov- 
entricularty (i.c.v.) or intrathecally (i.t.) under light halothane anesthe- 
sia on days 1, 3 and 5 as previously described (9 11 ). Analgesia was 
tested on day 6 in the tailflick assay 15 rain alter the injection of either 
morphine (0.7 yg, i.c.v, or 0.8/~g, i.t.) or morphine-6fl-glucuronide (20 
ng, i.c.v.). 
Analgesia was determined quantally in the radient heat tailflick assay 
as a doubling or greater of baseline tailflick latencies, as previously 
described [4,11.12,25 27,34,35]. A maximal atency of 10 sec was used 
to minimize any tissue damage. Gastrointestinal (GIt transit [11] was 
determined by comparing the distance traveled by a charcoal meal in 
morphine-treated (0.7/,tg, i.c.v.) mice compared to mice not receiving 
morphine. The control group received only vehicle without any oligode- 
oxynucleotide before receiving morphine. 
3. Resu l t s  
In the current  study we have mapped MOR- I  using antisense 
o l igodeoxynucleot ides directed against 1 l regions o f  the mouse 
MOR- I  mRNA which target all four exons (Table 1: Fig. l). 
First, we cloned the mouse version of  MOR- I  from a 5 ' -RACE 
ready cDNA.  Using our sequence, we designed a series o f  
antisense o l igodeoxynucleot ides target ing all four exons of  
MOR-1  and examined these probes against analgesia nd gas- 
trointest inal  transit. 
We examined the effects o f  antisense treatments on supraspi-  
nal morph ine  analgesia, a mu~ action (Table 1). A mismatch 
o l igodeoxynucleot ide based upon the antisense A has no signif- 
icant effect when compared  to saline controls.  In contrast.  
Ant isense A, targeting the 5 ' -untranslated region of  MOR- I ,  
dramatical ly  blocks morph ine  analgesia, conf i rming pr ior  re- 
ports  in the rat [25]. Ant isenses B and C, which are both di- 
rected against the open reading frame of  the first exon (Fig. 1). 
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Table 2 
Reversal of the inhibition of gastrointestinal transit by morphine by 
antisense 
Inhibition of GI transit n P 
Control 59.6 + 1.3% 65 
Antisense 
Exon 1 A 54.8 + 1.2% 50 NS 
B 46.3_+ 2.7% 10 NS 
C 46.8 + 2.9% 10 NS 
Exon 2 D 33.6_+ 3.0% 10 NS 
E 53.1 + 3.1% 8 NS 
F 65.1+ 1.8% 20 NS 
Exon 3 G 46.0 + 2.3% 9 NS 
H 46.1+1.7% 27 NS 
i 48.2_+ 2.7% 10 NS 
Exon 4 J 4.5 + 3.7% 10 <0.05 
K 66.5 + 1.4% 20 NS 
Groups of mice were treated intracerebroventricularly with the indi- 
cated antisense oligodeoxynucleotide on days 1, 3 and 5 and the effects 
of morphine (0.7 ,ug, i.c.v.) on gastrointestinal transit determined on 
day 6, as described in Section 2. The transit distance in mice not 
receiving morphine was 29.4 + 1.01 cm (n = 56) and the transit distance 
in the morphine alone treated mice was 11.9 + 0.84 cm. The sequences 
of the oligodeoxynucleotides andtheir positions are provided in Table 
1. ANOVA revealed significant differences among roups for the inhi- 
bition of GI transit and Sheffe's posthoc test revealed that only Anti- 
sense J was different. 
also effectively lower morphine analgesia. However, none of 
the antisense oligodeoxynucleotides based upon exon 2 are 
active. Of the three directed against exon 3, only Antisense I, 
located close to the junction with exon 4, lowers morphine 
analgesia. Antisense J, directed against the coding region of 
exon 4, potently blocks analgesia, but Antisense K from the 
3'-untranslated region does not. However, the significance of 
the inactivity of Antisense K is not clear since it is inactive 
against all actions examined (see below). 
We next examined two morphine actions mediated through 
mu2 receptors. Supraspinally, morphine inhibits gastrointesti- 
nal transit through mu2 receptors [1,44]. Only Antisense J, 
which targets exon 4, is effective against he inhibition of gas- 
trointestinal transit (Table 2). Despite their potent blockade of 
supraspinal morphine analgesia, none of the probes directed 
against exon 1 block the inhibition of gastrointestinal transit. 
We see similar results with spinal morphine analgesia, another 
mu 2 action (Table 3). Again, Antisense J potently blocks spinal 
analgesia, while all the other antisense oligodeoxynucleotides 
tested are inactive. Thus, the antisense activity profile for both 
mu2 actions is the same and distinct from supraspinal mul 
analgesia. 
Morphine-6fl-glucuronide (M6G) is an exceedingly potent 
morphine metabolite which also acts through mu receptors 
[11,12]. However, questions have arisen regarding its actions. 
In vivo, morphine-6fl-glucuronide is over 100-fold more potent 
an analgesic than morphine despite a lower affinity for mu 
receptors in binding assays [11,12] and in cyclase studies in 
neuroblastoma cell lines (K.M. Standifer, J. Ryan-Moro and 
G.W. Pasternak, unpublished observations). Thus, the far 
greater potency of morphine-6fl-glucuronide in vivo compared 
to morphine does not correspond to either increased binding 
affinity or intrinsic activity, raising the possibility that it might 
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be acting through a novel, previously unrecognized mu receptor 
subtype. Antisense mapping yields a very different picture for 
morphine-6fl-glucuronide analgesia (Table 4). The probes tar- 
geting exons 1 and 4 which potently block morphine analgesia 
are without effect on morphine-6fl-glucuronide analgesia. Con- 
versely, antisense probes directed against exons 2 and 3 all 
effectively block morphine-6fl-glucuronide actions. 
4. Discussion 
Antisense mapping can provide important insights in the 
correlation of the molecular biology and pharmacology of 
opioid receptors. Antisense mapping of DOR-1 in NG108-15 
cells and intrathecally in mice reveals imilar activities of all the 
antisense oligodeoxynucleotides r gardless of which exon is 
targeted [27], consistent with the suggestion that virtually all 
regions of mRNA are accessible to antisense oligodeoxynucle- 
otides [45]. Thus, the inactivity of antisense probes directed at 
a specific exon raises the possibility of an alternative xon, as 
illustrated by our prior studies with KOR-3 [34,35]. However, 
inactivity of an antisense oligodeoxynucleotide might result 
from a variety of technical factors, such as unanticipated sec- 
ondary mRNA structures. This concern is eliminated when 
the antisense oligodeoxynucleotide is active in at least one 
assay. All the antisense probes used in the current study were 
active in at least one assay, with the exception of Antisense K 
which targets the 3'-untranslated region. Its inactivity in all 
assays makes its actions impossible to interpret. However, the 
activity of all the other probes in at least one assay confirm that 
almost the entire length of the MOR-1 mRNA is accessible to 
the antisense oligodeoxynucleotides and that technical factors 
cannot be responsible for the differences in activity among the 
various antisense probes. 
The selectivity profiles of the antisense probes are not consis- 
tent with a single receptor and imply alternative splicing of the 
MOR-1 gene (Fig. 1). Pharmacological studies indicate that 
mul receptors produce supraspinal morphine analgesia while 
mu 2 receptors mediate spinal morphine analgesia nd the inhi- 
bition of gastrointestinal transit [1]. The antisense studies re- 
ported here are consistent with two mu receptor subtypes. Both 
mu subtypes appear to contain exon 4 which blocks all three 
morphine actions examined, but the activity of Antisenses A, 
B and C against only supraspinal analgesia suggests that exon 
Table 3 
Effect of antisense treatment on spinal morphine analgesia 
Analgesic response n P 
Control 69% 50 
Mismatch 53% 15 0.229 
Antisense 
Exon 1 A 70% 20 0.555 
Exon 2 D 50% 20 0.129 
Exon 3 H 75% 20 0.393 
I 56% 25 0.221 
Exon 4 J 36% 25 0.008 
Groups of mice received the indicated antisense oligodeoxynucleotide 
intrathecally on days 1, 3 and 5 and were tested for morphine analgesia 
on day 6 (0.8/lg, i.t.), as described in Section 2. The sequences of the 
oligodeoxynucleotides and their positions are provided in Table 1. 
Significance in the analgesic assays was assessed using the Fisher exact 
test. Statistically significant results are bolded. 
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Table 4 
Effect of antisense on morphine-6fl-glucuronide analgesia 
Analgesic response n P 
Control 73% 60 
Mismatch 80% 10 0.497 
Antisense 
Exon 1 A 55% 20 0.106 
B 72% 25 0.549 
( 55% 20 0.106 
Exon 2 D 5% 20 <0.0001 
E 24% 25 <0.0001 
F 34% 35 <0.001 
Exon 3 (i 32% 25 <0.001 
H 38% 40 <0.001 
1 30% 10 0.012 
Exon 4 J 90% 10 0.24 
K 52% 25 0.06 
Groups of mice received the indicated antisense oligodeoxynucleotide 
i.c.v, on days I, 3 and 5 and morphine-6fl-glucuronide (20 ng, i.c.v.) 
analgesia ssessed on day 6, as described in Section 2. The sequences 
of the oligodeoxynucleotides and their positions are provided in Table 
I. Significance in the analgesic assays was assessed using the Fisher 
exact test. Statistically significant results are bolded. 
1 is a component  of the mu,, but not the mu2 receptor. Anti- 
sense I, which targets exon 3 near the junct ion with exon 4, 
downregulates supraspinal analgesia without blocking either of 
the two mu, actions, providing further support for differences 
between the two mu subtypes. It is not clear why Antisense l 
is active against supraspinal morphine analgesia while the other 
two antisense probes targetting exon 3 are not. The similar 
ability of all three to prevent morphine-6fl-glucuronide analge- 
sia makes technical problems related to the activity of the anti- 
sense unlikely. The results could be explained by an alternative 
exon 3 which shares some sequence with exon 3 in MOR-  I. We 
cannot yet assess relationships of exons 2 in the putative mu~ 
and mu~ receptors. 
The antisense profile against morphine-6~-glucuronide anal- 
gesia dramatical ly differs from that of morphine, implying that 
its actions result from yet another splice variant. The activity 
of the antisense oligodeoxynucleotides directed against exons 
2 and 3 suggest hat they are included within the morphine-6fl- 
glucuronide receptor while exons 1 or 4 are not. The presence 
of a distinct morphine-6fl-glucuronide receptor would help ex- 
plain the apparent inconsistency between its binding and 
cyclase activity at tradit ional mu receptors and its extraordi- 
nary potenc~ in vivo. The possibility that the mu receptor 
subtypes and the morphine-6fl-glucuronide receptor epresent 
splice variants leaves the important question of the role of 
MOR-I  in opioid pharmacology. 
Despite the high abundance of its mRNA in the brain, its 
actions and pharmacological significance is unknown. In con- 
clusion, these results suggest hat the various mu receptor sub- 
types postulated from binding and pharmacological studies re- 
sult from ahernative splicing of MOR-1 and predict a novel 
receptor within the mu family for morphine-6fl-glucuronide. 
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